Clinical trials: Schizophrenia
Healthy Subjects
Study Evaluating HTC-867 in Healthy Young and Elderly Subjects
The purpose of this study is to assess the safety and tolerability of ascending single oral doses of HTC-867 in healthy young and elderly subjects.
- Trial name
- NCT00827489
- Testing
- HTC-867
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Agitation
Phase IV to Evaluate the Safety of Self-administered ADASUVE® in Agitated Patients Outside the Hospital Setting
Phase IV, multinational, multicentre, open-label, non-randomized, clinical trial conducted in Europe (Spain, Germany, Finland, Norway, Romania and Austria) to evaluate the safety profile of ADASUVE® in agitated patients with…
- Trial name
- NCT02525991
- Testing
- Staccato® Delivery System Loxapine (ADASUVE®)
- Where
- Spain
- Volunteers
- 323 people
- Sponsor
- Ferrer Internacional S.A.
Schizophrenia
A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia
This Phase 3, multi-center, randomized, double blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in participants with persistent, predominant negative symptoms of…
- Trial name
- NCT01192880
- Testing
- Bitopertin, Antipsychotics
- Where
- 103 sites in United States, Bulgaria and 5 more
- Volunteers
- 625 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia, Major Depressive Disorder
"Brexpiprazole (Rexulti™) Safety and Efficacy Among Filipino Patients (RAISE) - A Post Marketing Surveillance Program"
The objective of this post marketing surveillance is to further gather local data on the safety and efficacy of Brexpiprazole (RexultiTM) Film-coated Tablet in the treatment of schizophrenia and adjunctive therapy of Major…
- Trial name
- RAISE (NCT04641780)
- Testing
- Brexpiprazole
- Where
- Philippines
- Volunteers
- 300 people
- Sponsor
- Otsuka Pharmaceutical, Inc., Philippines
Schizophrenia, Schizoaffective Disorder
Health Evaluation of Abilify Long-term Therapy
This is a post-market surveillance, and the treatment to patients will be depended upon the decision based on physician's clinical judgment.
- Trial name
- HEALTH (NCT00520650)
- Testing
- Aripiprazole
- Where
- 9 sites in Taiwan
- Volunteers
- 245 people
- Sponsor
- Taiwan Otsuka Pharm. Co., Ltd
Schizophrenic Disorders
Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia
This is a randomized, double-blind study to determine how well intramuscular (IM) olanzapine depot works compared to oral olanzapine; evaluate the safety and tolerability of IM olanzapine depot compared to oral olanzapine…
- Trial name
- NCT00088491
- Testing
- Intramuscular Olanzapine Depot, Oral Olanzapine
- Where
- 4 sites in Finland, Turkey (Türkiye)
- Volunteers
- 1,205 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia
This study aims to evaluate whether PF-02545920 is safe and effective in the treatment of sub-optimally controlled symptoms of schizophrenia during a 12-week outpatient treatment period.
- Trial name
- NCT01939548
- Testing
- PF-02545920
- Where
- 44 sites in United States
- Volunteers
- 240 people
- Sponsor
- Pfizer
Schizophrenia
A Non-interventional Study Evaluating the Clinical Benefit and Effectiveness of Quetiapine Fumarate Extended
The primary objective of this NIS is to assess the clinical benefit subjects derive from taking seroquel XR, using the CGI-CB. The secondary objective is to assess the effectiveness,safety and tolerability of seroquel XR tablets.
- Trial name
- CLIMAX (NCT00922090)
- Where
- 11 sites in South Korea
- Volunteers
- 1,494 people
- Sponsor
- AstraZeneca
Schizophrenia
A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia
The purpose of this study is to evaluate the efficacy of the drug SM-13496 compared to a placebo and to haloperidol in patients with schizophrenia.
- Trial name
- NCT00044044
- Testing
- Lurasidone 20 mg, Lurasidone 40mg, Lurasidone 80 mg
- Where
- 34 sites in United States
- Volunteers
- 356 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia
A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia
To investigate the efficacy and safety of OPC-34712 in comparison with placebo in patients with schizophrenia.
- Trial name
- NCT01451164
- Testing
- OPC-34712
- Where
- Japan
- Volunteers
- 459 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia, Schizoaffective Disorder
Study on the Safety and Effectiveness of Risperidone Treatment of Acute Psychotic Patients
The purpose of this study was to evaluate the safety of risperidone treatment in acute psychotic patients that require an admission into emergency department.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
- Trial name
- NCT00515489
- Testing
- Risperidone
- Volunteers
- 1,882 people
- Sponsor
- Janssen-Cilag, S.A.
Schizophrenia
Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients
The primary objective of the study is to evaluate changes in weight short and long term with bifeprunox and quetiapine. Study participation for the subject is 57 weeks.
- Trial name
- NCT00396214
- Testing
- Bifeprunox, Quetiapine
- Where
- 151 sites in United States, Argentina and 12 more
- Volunteers
- 83 people
- Sponsor
- Solvay Pharmaceuticals
Schizophrenia
The Bioequivalence Of Two Different Lurasidone Formulations In Patients
A Phase I, Bioequivalent Study between 2 Formulations of Lurasidone HCl
- Trial name
- NCT01082250
- Testing
- Lurasidone HCl
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia, Major Depressive Disorder (MDD)
A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive Episode
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple dose oral administration of SEP-380135 in participants with schizophrenia or with a major depressive…
- Conditions
- Schizophrenia, Major Depressive Disorder (MDD), Bipolar Disorder
- Trial name
- NCT07549581
- Testing
- SEP-380135
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Placebo-Controlled Study of Physiologic Effects of L-methylfolate in Schizophrenia Patients
This study is a 12-week, double-blind, placebo-controlled trial of L-methylfolate 15 mg/d supplementation in schizophrenia patients with mild or greater negative symptoms.
- Trial name
- NCT01091506
- Testing
- L-methylfolate
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Pamlab, Inc.
Schizophrenia
Multiple Dose Safety Study of PF-04802540 in Subjects With Schizophrenia
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple ascending doses of PF-04802540 administered orally to subjects with schizophrenia.
- Trial name
- NCT00876304
- Testing
- PF-04802540
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Taisho Pharmaceutical Co., Ltd.
Schizophrenia
Relapse Prevention Study in Patients With Schizophrenia
The purpose of this study is to determine whether Iloperidone is effective in the prevention of relapse in patients with schizophrenia
- Trial name
- REPRIEVE (NCT01291511)
- Testing
- Iloperidone
- Where
- 63 sites in United States, India and 1 more
- Volunteers
- 635 people
- Sponsor
- Vanda Pharmaceuticals
Schizophrenia
Managing Acute Schizophrenia, a Comparison Between Two Atypical Antipsychotics
The purpose of this study is to examine whether olanzapine, compared to risperidone, can provide more adequate and timely control of behavioral agitation in acutely ill subjects with schizophrenia.
- Trial name
- NCT00485498
- Testing
- Olanzapine Hydrochloride, Risperidone
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
A Comparative Study of Paliperidone Palmitate and Risperidone Long Acting Injection (LAI) in Participants With Schizophrenia
The purpose of this study is to compare the efficacy of paliperidone palmitate and risperidone long acting injection (LAI) in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability…
- Trial name
- NCT00604279
- Testing
- Paliperidone palmitate (R092670), Risperidone
- Where
- 8 sites in China
- Volunteers
- 452 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Schizophrenia, Schizoaffective Disorder
Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
The purposes of this study are to assess the efficacy, safety, and side effects among doses approved by the Food and Drug Administration and higher (not FDA approved) doses of olanzapine in patients with schizophrenia or…
- Trial name
- NCT00100776
- Testing
- Olanzapine
- Where
- 33 sites in United States
- Volunteers
- 600 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.